Clinical Trial Update: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) [Phase 1, Phase 2]

View source ↗

Summary

Neurona Therapeutics reports a Phase 1/2 clinical trial of NRTX-1001, a neuronal cell therapy, for drug-resistant bilateral mesial temporal lobe epilepsy (MTLE)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Temporal Lobe Epilepsy

Drugs mentioned

• NRTX-1001 (NRTX-1001)

Snippet

Sponsor: Neurona Therapeutics | Conditions: Epilepsy, Temporal Lobe | Phase 1, Phase 2 | Status: RECRUITING